Stimulant Induced Movement Disorders in Attention Deficit Hyperactivity Disorder

Overview

Journal Soa Chongsonyon Chongsin Uihak

Date 2022 Apr 14

PMID 35418800

Authors

Seok-Hyun Nam

Myung Ho Lim

Tae Won Park

Affiliations

Soon will be listed here.

Abstract

Stimulants, such as amphetamine and methylphenidate, are one of the most effective treatment modalities for attention deficit hyperactivity disorder (ADHD) and may cause various movement disorders. This review discusses various movement disorders related to stimulant use in the treatment of ADHD. We reviewed the current knowledge on various movement disorders that may be related to the therapeutic use of stimulants in patients with ADHD. Recent findings suggest that the use of stimulants and the onset/aggravation of tics are more likely to be coincidental. In rare cases, stimulants may cause stereotypies, chorea, and dyskinesia, in addition to tics. Some epidemiological studies have suggested that stimulants used for the treatment of ADHD may cause Parkinson's disease (PD) after adulthood. However, there is still a lack of evidence that the use of stimulants in patients with ADHD may cause PD, and related studies are only in the early stages. As stimulants are one of the most commonly used medications in children and adolescents, close observations and studies are necessary to assess the effects of stimulants on various movement disorders, including tic disorders and Parkinson's disease.

Citing Articles

Methylphenidate differentially affects the social ultrasonic vocalizations of wild-type and prodromal Parkinsonian rats.

Lechner S, Kelm-Nelson C, Ciucci M Behav Neurosci. 2024; 139(1):1-9.

PMID: 39509189 PMC: 11747832. DOI: 10.1037/bne0000610.

A complex case of young child with ADHD, developmental delay who developed seronegative autoimmune encephalitis exacerbated by stimulants.

Saliba M, Wilton A, Hagen K, Romanowicz M Brain Behav Immun Health. 2023; 34:100692.

PMID: 37842135 PMC: 10569956. DOI: 10.1016/j.bbih.2023.100692.

References

Sverd J, Gadow K, Paolicelli L . Methylphenidate treatment of attention-deficit hyperactivity disorder in boys with Tourette's syndrome. J Am Acad Child Adolesc Psychiatry. 1989; 28(4):574-9; discussion 580-2. DOI: 10.1097/00004583-198907000-00016. View

Varley C, Vincent J, Varley P, Calderon R . Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medications. Compr Psychiatry. 2001; 42(3):228-33. DOI: 10.1053/comp.2001.23145. View

. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002; 58(4):527-36. DOI: 10.1212/wnl.58.4.527. View

Scheffler R, Hinshaw S, Modrek S, Levine P . The global market for ADHD medications. Health Aff (Millwood). 2007; 26(2):450-7. DOI: 10.1377/hlthaff.26.2.450. View

Sukhodolsky D, Scahill L, Zhang H, Peterson B, King R, Lombroso P . Disruptive behavior in children with Tourette's syndrome: association with ADHD comorbidity, tic severity, and functional impairment. J Am Acad Child Adolesc Psychiatry. 2002; 42(1):98-105. DOI: 10.1097/00004583-200301000-00016. View

Kakish J, Lee D, Lee J . Drugs That Bind to α-Synuclein: Neuroprotective or Neurotoxic?. ACS Chem Neurosci. 2015; 6(12):1930-40. DOI: 10.1021/acschemneuro.5b00172. View

Faraone S . Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths. P T. 2010; 34(12):678-94. PMC: 2810184. View

Moszczynska A, Fitzmaurice P, Ang L, Kalasinsky K, Schmunk G, Peretti F . Why is parkinsonism not a feature of human methamphetamine users?. Brain. 2003; 127(Pt 2):363-70. DOI: 10.1093/brain/awh046. View

Bloch M, Leckman J . Clinical course of Tourette syndrome. J Psychosom Res. 2009; 67(6):497-501. PMC: 3974606. DOI: 10.1016/j.jpsychores.2009.09.002. View

10.

Curtin K, Fleckenstein A, Keeshin B, Yurgelun-Todd D, Renshaw P, Smith K . Increased risk of diseases of the basal ganglia and cerebellum in patients with a history of attention-deficit/hyperactivity disorder. Neuropsychopharmacology. 2018; 43(13):2548-2555. PMC: 6224615. DOI: 10.1038/s41386-018-0207-5. View

11.

Asser A, Taba P . Psychostimulants and movement disorders. Front Neurol. 2015; 6:75. PMC: 4403511. DOI: 10.3389/fneur.2015.00075. View

12.

Todd G, Pearson-Dennett V, Wilcox R, Chau M, Thoirs K, Thewlis D . Adults with a history of illicit amphetamine use exhibit abnormal substantia nigra morphology and parkinsonism. Parkinsonism Relat Disord. 2016; 25:27-32. DOI: 10.1016/j.parkreldis.2016.02.019. View

13.

Stokes A, Bawden H, Camfield P, Backman J, Dooley J . Peer problems in Tourette's disorder. Pediatrics. 1991; 87(6):936-42. View

14.

Garwood E, Bekele W, McCulloch C, Christine C . Amphetamine exposure is elevated in Parkinson's disease. Neurotoxicology. 2006; 27(6):1003-6. DOI: 10.1016/j.neuro.2006.03.015. View

15.

Erenberg G, Cruse R, Rothner A . Gilles de la Tourette's syndrome: effects of stimulant drugs. Neurology. 1985; 35(9):1346-8. DOI: 10.1212/wnl.35.9.1346. View

16.

Pierre C, Nolan E, Gadow K, Sverd J, Sprafkin J . Comparison of internalizing and externalizing symptoms in children with attention-deficit hyperactivity disorder with and without comorbid tic disorder. J Dev Behav Pediatr. 1999; 20(3):170-6. DOI: 10.1097/00004703-199906000-00006. View

17.

Zito J, Safer D, dosReis S, Gardner J, Magder L, Soeken K . Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med. 2003; 157(1):17-25. DOI: 10.1001/archpedi.157.1.17. View

18.

Baumeister A, Henderson K, Lee Pow J, Advokat C . The early history of the neuroscience of attention-deficit/hyperactivity disorder. J Hist Neurosci. 2012; 21(3):263-79. DOI: 10.1080/0964704X.2011.595649. View

19.

Camicioli R, Lea E, Nutt J, Sexton G, Oken B . Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: a pilot study. Clin Neuropharmacol. 2001; 24(4):208-13. DOI: 10.1097/00002826-200107000-00003. View

20.

Moll G, Hause S, Ruther E, Rothenberger A, Huether G . Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters. J Child Adolesc Psychopharmacol. 2001; 11(1):15-24. DOI: 10.1089/104454601750143366. View